REG1 [anivamersen-pegnivacogin] versus pegnivacogin alone in patients with stable coronary artery disease receiving aspirin +/- clopidogrel
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2008
At a glance
- Drugs Anivamersen-pegnivacogin (Primary) ; Pegnivacogin
- Indications Coronary artery disease; Venous thrombosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Regado Biosciences
- 03 Sep 2008 Results have been published in the proceedings of the ESC Congress 2008: Annual Congress of the European Society of Cardiology.
- 12 Nov 2007 New trial record.